Connect with us

BioPharma

Darkpulse Inc (OTCMKTS: DPLS) Powerful Reversal Brewing as Global Leader in Distributed Fibre Sensor Solutions BOTDA Gains Traction (Update on: Caltrans, Optilan, Acquisitions)

Published

on

Darkpulse Inc (OTCMKTS: DPLS) volume is picking up substantially as the stock is once again below a nickel trading $4.3 million in dollar volume on Friday alone. DPLS made a spectacular run up the charts in 2021 topping out in July at $0.202 highs. At current levels DPLS is under heavy accumulation from a fast-growing shareholder base who sees big things happening here. DPLS is looking to break out into a whole new dimension – a break over $0.202 and its blue skies ahead for DPLS. We first reported on DPLS when the stock was less than $0.01 in January, 2020 stating at the time: “DPLS is making a strong move up in recent weeks off its triple zero lows to recent highs over $0.02. DPLS has attracted legions of new shareholders and is quickly emerging as a volume leader in small caps topping $13 million in dollar volume on Friday alone.” 

DPLS is a leader in distributed fiber sensor solutions whose proprietary patented system outperforms all other distributed fiber sensors currently on the market. The Company boasts a growing list of world-class capabilities and is positioning itself as the leader in infrastructure sensing and monitoring in all domains, air, land, and sea which represents an enormous market worth billions putting Darkpulse in line for serious government contracts according to many investors who are accumulating at current levels. Darkpuse continues to make big moves with the recent acquisition of Optilan which recently secured leases for two new facilities located in Warwickshire in the U.K. DPLS plans to take Optilan public on the New York Stock Exchange (“NYSE”) in mid-2022 via an initial public offering (IPO). DPLS management plans to retain 80% ownership of Optilan. DPLS also entered into a pilot project in California to monitor the structural health of bridges and roadbeds with the California Department of Transportation. CALTRANS is the first smart bridge in the world and an amazing opportunity for the Company. DPLS management team continues to work hard behind the scenes; they filed a complaint against CD holder FirstFire Global Opportunity Fund, LLC in the amount of $38,825,725.00. According to management the Company has filed 3 complaints recently against alleged securities act violators. DPLS BOD has also authorized a stock repurchase program under which the Company can repurchase up to $15,000,000 of the currently outstanding shares of the Company’s common stock. 

Darkpulse Inc (OTCMKTS: DPLS) offers a full suite of engineering, installation and security management solutions to industries and governments. Coupled with its patented BOTDA dark-pulse technology, DarkPulse provides its customers a comprehensive data stream of critical metrics for assessing the health and security of their infrastructure. The Company’s comprehensive system provides for rapid, precise analysis and responsive activities predetermined by the end-user customer. By contrast to existing technologies, the DarkPulse Technology is a distributed-fiber sensing system, based on dark-pulse Brillouin scattering, which reports in real-time on conditions such as temperature, stress, strain corrosion and structural health monitoring of Critical Infrastructure/Key Resources including Bridges, Buildings, Roadways pipelines and mining installations. DarkPulse Technology’s differentiators from and advantages over existing technologies by offering Real-time Reporting: Higher data acquisition speeds allowing for structural monitoring of dynamic systems. Cost to Customer: Significantly lower acquisition and operating costs. Precision: A greater magnitude of precision and spatial resolution than other systems currently available. Applications: Wider range of capabilities than other systems currently available. Power consumption: Lower power consumption than existing systems allowing for off-grid installations. Integration: Capable of integrating with existing systems. Central station monitoring/cloud-based GUI. DarkPulse BOD recently authorized a stock repurchase program under which the Company can repurchase up to $15,000,000 of the currently outstanding shares of the Company’s common stock, over a period of 12 months through open market purchases, or privately-negotiated transactions. The Company also engaged RedChip Companies to lead its investor relations efforts. DPLS is already generating revenues; for the 3 months ended September 30, 2021 DPLS reported $3,500,970 in sales. 

The Company is led by CEO Dennis O’Leary, a serial entrepreneur with significant international experience having founded Sulu Electric Power and Light Corp (Philippines), a firm with expertise in utility scale power generation and solar energy. He is the co-founder and Chairman of DarkPulse Technologies Inc., a firm developing specialized devices that monitor activities along national borders and provide structural health and safety monitoring of oil and gas pipelines. Mr. O’Leary will be one of the Keynote Speakers at the “Future Cities in the New Republic” Conference in Cairo Feb 26 & 27, 2022 to discuss the development of Smart Cities through Digital Transformation on Architecture and Urbanization in Egypt. 

In this video engineers demonstrate the function of the dark-pulse based BOTDA system measuring strain on a PVC pipe. A 4″ PVC pipe specimen with 12′ length has a sensing fibre helically wrapped around it which measures the hoop strain as the pressure in the pipe is raised. Data is first collected at an internal pressure of 10 psig. The engineers then clamp one end of the pipe creating a disturbance in the strain field. This disturbance is readily seen in the second measurement demonstrating dark-pulse BOTDA system’s ability to detect sub-metre strain events. DarkPulse offers multiple configurations with increased processor capacity for faster data display including a cloud-based GUI as part of 24/7 structural health monitoring solutions. Darkpulse is a leader in distributed fiber sensor solutions. DPLS system outperforms all other distributed fiber sensors in the market today. DarkPulse’s growing list of world-class capabilities and the Company’s positioning as the leader in infrastructure sensing and monitoring in all domains, air, land, and sea which represents an enormous market worth billions puts Darkpulse in line for serious government contracts according to many investors who are buying in here. The Company continues to grow fast through acquisition. 

To Find out the inside Scoop on DPLS Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

DPLS

DPLS has been busy in January; they filed a complaint against a convertible note debt funder for multiple alleged federal securities laws violations and is seeking the return of all stock (or its cash equivalent) amounting to $38,825,725.00 that may have been unlawfully taken by the defendant FirstFire Global Opportunity Fund, LLC. It is managements intention to take any award by the courts and issue a special dividend to all shareholders of record in DPLS (in the event cash is recovered). This way, the shareholders may have the ability to get back what was taken from them. However, there is no guarantee that DPLS will be successful in such lawsuits. They also filed a complaint against EMA Financial, LLC, and its manager, Felicia Preston for multiple alleged federal securities laws violations and is seeking the return of all stock (or its cash equivalent) that may have been unlawfully taken through convertible note conversions. According to management the Company has filed 3 complaints recently against alleged securities act violators. 

Darkpulse also recently announced its intention to take its wholly-owned subsidiary, Optilan public in the U.S. in mid-2022 via an initial public offering (IPO). Management believes the move will unlock the value of Optilan for DarkPulse shareholders by creating a separate publicly traded company and will build on Optilan’s successful track record and serve to expand its markets. The Company anticipates that Optilan will apply for listing on the New York Stock Exchange (“NYSE”) directing towards public offering upon acceptance. The company plans to list 20% of Optilan shares on the NYSE while retaining 80% ownership. Optilan will remain a subsidiary of DarkPulse and the two companies will continue as strategic partners. 

With relatively independent business operations, Optilan is an infratech consulting and solution services provider that covers various technology-driven industries including but not limited to telecommunications, oil and gas, alternative energy, rail solutions, and power. For more than 30 years, Optilan has been enabling its customers to increase operational efficiencies across all these industries with advanced security and communication solutions protecting their customers’ assets. DarkPulse has been and will continue to engage with in-demand technologies such as big data, artificial intelligence (AI), cloud computing, robotics, defense and aerospace, among others. DarkPulse’s main focus will remain on smart infrastructure and, as the world moves toward smart cities, the focus will expand to include the implementation of Global System Dynamics as part of the Company’s SaaS model as it continues to expand its global footprint. Optilan is already on this journey with its fiber-related business helping enable faster connectivity to the web. DarkPulse has no intention of spinning off or otherwise divesting its majority ownership interest. A final decision on the IPO and its conditions and ultimate timing is pending and subject to market conditions. 

On January 13 DPLS CEO Dennis O’Leary went on the Stock Day Podcast to discuss the CALTRANS Project, Middle East Expansion, and Optilan IPO with The Stock Day Podcast. Mr. O’Leary stated: “Right now we are a total of seven companies. We have purchased a series of patents on something called dark pulsing, which is a sensing technology. We took the company public in 2018 and we are headed towards data-as-a-service. We are opening an office in Dubai, as well as an office in Abu Dhabi. The plan is to open an office in Egypt as well.” 

On CALTRANS; the Company’s pilot project with the California Department of Transportation Mr. O’Leary commented: “CALTRANS is the first smart bridge in the world,” said O’Leary, before elaborating on the in-depth stress, strains, and data that the smart bridge will be able to provide. “It is an amazing opportunity,” he added. “The California Department of Transportation sets the standard and other DOTs follow it.” 

For More on DPLS Subscribe Right Now!

DPLS volume is picking up substantially as the stock is once again below a nickel trading $4.3 million in dollar volume on Friday alone. DPLS made a spectacular run up the charts in 2021 topping out in July at $0.202 highs. At current levels DPLS is under heavy accumulation from a fast-growing shareholder base who sees big things happening here. DPLS is looking to break out into a whole new dimension – a break over $0.202 and its blue skies ahead for DPLS. We first reported on DPLS when the stock was less than $0.01 in January, 2020 stating at the time: “DPLS is making a strong move up in recent weeks off its triple zero lows to recent highs over $0.02. DPLS has attracted legions of new shareholders and is quickly emerging as a volume leader in small caps topping $13 million in dollar volume on Friday alone.” DPLS is a leader in distributed fiber sensor solutions whose proprietary patented system outperforms all other distributed fiber sensors currently on the market. The Company boasts a growing list of world-class capabilities and is positioning itself as the leader in infrastructure sensing and monitoring in all domains, air, land, and sea which represents an enormous market worth billions putting Darkpulse in line for serious government contracts according to many investors who are accumulating at current levels. Darkpuse continues to make big moves with the recent acquisition of Optilan which recently secured leases for two new facilities located in Warwickshire in the U.K. DPLS plans to take Optilan public on the New York Stock Exchange (“NYSE”) in mid-2022 via an initial public offering (IPO). DPLS management plans to retain 80% ownership of Optilan. DPLS also entered into a pilot project in California to monitor the structural health of bridges and roadbeds with the California Department of Transportation. CALTRANS is the first smart bridge in the world and an amazing opportunity for the Company. DPLS management team continues to work hard behind the scenes; they filed a complaint against CD holder FirstFire Global Opportunity Fund, LLC in the amount of $38,825,725.00. According to management the Company has filed 3 complaints recently against alleged securities act violators. DPLS BOD has also authorized a stock repurchase program under which the Company can repurchase up to $15,000,000 of the currently outstanding shares of the Company’s common stock. We will be updating on DPLS when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with DPLS.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in DPLS either long or short and we have not been compensated for this article.

Continue Reading
2 Comments

2 Comments

  1. Jim Brash

    February 25, 2022 at 2:06 pm

    Boe, I wish u did a few educational articles on how to invest in micro caps and how to spot genuine growth stocks as opposed to scams or pump and dumps. It would be greatly appreciated. I’d be willing to pay for that kind of insight.

  2. Boe Rimes

    March 6, 2022 at 10:56 pm

    Thanks Jim I will try that

Leave a Reply

Your email address will not be published. Required fields are marked *

BioPharma

Advancing Medical Frontiers: Elutia Inc.’s(NASDAQ: ELUT) Strategic Vision in a $600 Million Market

Published

on

Elutia Inc (NASDAQ: ELUT) shares bolstered a whopping 33% today as the company recently shared that they’ve secured about $10.5 million in funding through a private investment round. If all the warrants are cashed in as part of this funding, the total could go up to $26.2 million.

Latest Changes:

Just last week, Aziyo Biologics changed its name to Elutia Inc. Following this change, Elutia made an announcement about selling its Orthobiologics business unit to Berkeley Biologics, a subsidiary of GNI Group Ltd. This move is set to bring in a substantial amount of cash, totalling up to $35 million for Elutia. This sum includes a notable upfront payment of $15 million, plus additional potential earnings of up to $20 million over five years. The deal is expected to be finalized in the fourth quarter of 2023.

This sale is a big step for Elutia, especially in the realm of drug-eluting biomatrix technology (DEB). Elutia is actively seeking approval from the FDA for their main product, CanGaroo RM. This product utilizes innovative biomatrix technology with antibiotics rifampin and minocycline (RM), providing long-term protection for cardiac pacemakers and defibrillators. This tackles a huge market estimated to be worth around 600 million. Elutia is aiming to introduce CanGaroo RM to the market in the first half of 2024.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below. 

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Standard Of Care:

Medtronic (NYSE: MDT) stands as the exclusive provider of the antibiotic envelope within the current market. This envelope is crafted using synthetic mesh infused with antibiotics. Back in 2014, Medtronic acquired this technology, making a strategic investment of up to $200 million. Primarily intended for Cardiac Implantable Electronic Device (CIED) revision procedures, this product boasts estimated annual sales in the range of $250 to $300 million.

However, despite its market presence and revenue generation, the Medtronic antibiotic envelope has notable limitations. While it effectively combats infections, its synthetic composition renders it less effective in supporting wound healing. Moreover, it poses challenges in accommodating larger devices like Subcutaneous Implantable Defibrillators (SCID).

Drug-eluting biomatrix (DEB):

Drug-eluting biomatrix (DEB) involves a specialized approach to drug delivery using a biomatrix as a carrier or platform. In simple terms, it’s a technique where a biomaterial matrix, often a biocompatible polymer or similar substance, is used to release drugs in a controlled and targeted manner.

The biomatrix acts as a support structure that can hold and gradually release drugs or therapeutic agents at a specific site in the body, typically over an extended period. This is particularly useful in medical applications where a localized and sustained delivery of medication is necessary.

For instance, in the context of Elutia’s CanGaroo RM, a biomatrix incorporating antibiotics rifampin and minocycline is used to provide prolonged protection for cardiac pacemakers and defibrillators. The biomatrix slowly releases these antibiotics at the surgical site, preventing infections and promoting healing.

DEB technology is gaining traction because it enhances treatment efficiency by ensuring the drug is delivered directly to the target area, minimizing side effects, and optimizing therapeutic outcomes. It’s a promising approach in the field of medical advancements, especially in areas like cardiology, oncology, and orthopedics.

Post-mastectomy Breast Reconstruction:

On top of this, the company also has plans to develop an RM version of its SimpliDerm biomatrix tailored for breast reconstruction procedures. The rate of infections after this surgery is quite high, more than 10%, highlighting a big medical need in a market valued at over $500 million. Elutia is stepping up to address this issue by developing SimpliDerm® RM, which incorporates their unique DEB technology. The funds raised through the private investment round (PIPE) and the sale of the Orthobiologics business unit will not only boost Elutia’s efforts in advancing their drug-eluting biomatrix products for the cardiac pacemaker and defibrillator market, but also for post-mastectomy breast reconstruction.

What’s next:

As mentioned earlier, their biomatrix platform serves two major markets. CanGaroo RM, their upcoming product, is slated for a 1H of 2024 market release and is poised to be a pioneer in a $600 million market. Furthermore, their SimpliDerm RM product utilizes the same proprietary antibiotic-eluting technology found in CanGaroo RM, which serves a 1.6B market according to their presentation deck. They aim to secure an IDE by Q4 2024, and upon achieving these milestones, they plan to venture into neurostimulator markets, particularly in pain management, to further drive their growth.

We will update you on ELUT when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by sasint from Pixabay

Continue Reading

BioPharma

ZyVersa Therapeutics’ (NASDAQ: ZVSA) Breakthrough: A Super Tool for Tackling Inflammation in ALS and Beyond

Published

on

ZyVersa Therapeutics (NASDAQ: ZVSA) had a spectacular day on the market, with its stock surging by almost 50% following a significant announcement about one of their promising drug candidates, IC-100. This drug is designed to combat inflammation in the context of Inflammatory Diseases, and the latest data is incredibly promising. For those who are new to this field of investment, we’ve taken the liberty of rephrasing the press release in simpler terms.

The Release:

When you’re dealing with diseases like ALS that affect your brain and nerves, shutting down the inflammasome pathway NLRP3 (a multi-protein that regulates the immune system and inflammatory signaling), is not enough.

To address this, ZyVersa is working on something called Inflammasome ASC Inhibitor IC-100. It’s like a super tool designed to block not just NLRP3 but a bunch of other inflammasome pathways too – up to 12 of them. This helps keep inflammation in check, whether it’s in the central nervous system (CNS) or other parts of the body where inflammation is causing problems.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

In a recent paper published in Frontiers in Immunology, they pointed out that focusing only on NLRP3 might not do the trick when it comes to calming CNS inflammation in ALS and similar diseases. They did experiments with cells and even used mice to back up their point. Turns out, just targeting NLRP3 didn’t stop the release of those pesky proinflammatory chemicals or the damage they were causing in the spinal cord.

The authors of the paper basically said, “Maybe we should aim to tackle multiple inflammasome pathways when it comes to diseases like ALS, where lots of inflammasomes are going haywire.”

The CEO and president at ZyVersa, Stephen C. Glover mentioned “Our research shows that to really put the brakes on inflammation driven by multiple inflammasomes, we need more than just NLRP3 inhibition.” He added that IC-100 is like a superhero in the world of inflammation control. It stops the formation of different types of inflammasomes, preventing the start of the inflammation chain reaction, and also puts a halt to something called ASC specks, which keep the inflammation going. You can dive deeper into how IC 100 works by checking out their website here.

So, in plain speak, ZyVersa is cooking up a promising solution for folks dealing with inflammation-related problems, especially those tied to the brain and nerves. They’re not just focusing on one troublemaker; they’re going after a whole gang to keep things under control.

Overall ZyVersa is a company on a mission to create groundbreaking treatments for kidney and inflammatory diseases, and IC-100 could help them in this mission.

We will update you on ZVSA when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by swiftsciencewriting from Pixabay

Continue Reading

BioPharma

Creative Medical Technology NASDAQ: CELZ) Major Breakthrough: Allogeneic Cell Line Paves the Way for Diabetes Treatment

Published

on

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) has recently seen a substantial intraday gain of over 15% in its share price. Despite the absence of any recent news or filings, this surge could suggest significant progress in the realm of allogeneic cell therapy.

Background:

The company is known for its regenerative approaches in various medical areas, including immunotherapy, endocrinology, urology, gynecology, and orthopedics, and made a significant announcement. In the fourth quarter of 2022,They successfully developed a new allogeneic cell line called AlloStem™. AlloStem™ is derived from human perinatal tissue and includes a Master Cell Bank and a Drug Master File. Now, with FDA approval, their program, known as CELZ-201, is being used in an early clinical trial for type 1 diabetes and will continue to be developed for both type 1 and type 2 diabetes treatment.

Additionally, the company is using the AlloStem™ line for its StemSpine® procedure to help treat chronic back pain. They report remarkable results, including over a 90% reduction in narcotic usage, more than an 80% reduction in pain scores, and over a 50% reduction in the Oswestry score in patients treated with AlloStem™.

Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Allogeneic Cell Therapy:

Allogeneic Cell Therapy is a treatment that uses cells from healthy donors to treat patients with otherwise untreatable diseases. These cells can come from various sources, like bone marrow, blood, or umbilical cord blood. This approach shows great promise in the medical field.

Allogeneic cell therapy offers potentially curative options for patients when traditional treatments fall short. While still a relatively new field, ongoing research into allogeneic cell therapies holds great potential for patients suffering from these diseases. Companies like Argan Inc. are also exploring the benefits of allogeneic cells.

With FDA approval and ongoing clinical trials, Creative Medical Technology’s recent developments open doors to innovative treatments that could significantly enhance the lives of those dealing with diabetes and other diseases. The global market for allogeneic cell therapy reached $255.6 million in 2022 and is expected to grow at a rate of 27.4% from 2023 to 2030, emphasizing the importance of continued research. As the company remains dedicated to medical innovation, their efforts have the potential to improve the health outcomes of people worldwide.

Latest Release:

The company recently shared key updates on its financial status and drug pipeline for Q3 2023. The biotech company, known for its regenerative medical solutions, reported being debt-free with $14.6 million in cash and $14.4 million in working capital, sufficient to cover expenses through 2024.

Their advancements in treating type 1 diabetes include FDA clearance for a groundbreaking clinical trial using CELZ-201 (AlloStem™). The company obtained Institutional Review Board approval and partnered with Syneos Health for this study. They also filed for Orphan Drug Designation to tackle brittle type 1 diabetes.

Promising results emerged from the CELZ-001 treatment for type 2 diabetes, demonstrating substantial reductions in insulin requirements with no safety concerns.

A pilot study on the StemSpine® procedure, using donor cells (AlloStem), showed impressive reductions in narcotic usage, pain scores, and improved functionality for chronic lower back pain patients.

Creative Medical Technology’s ImmCelz platform proved efficient, requiring fewer donor cells and yielding high-quality results.

They also collaborated with Greenstone Biosciences Inc. to develop a human-induced pluripotent stem cell (iPSC) pipeline, iPScelzTM, aimed at expediting drug discovery. The development of this cell line is expected to save the company two to three years in research and development time, along with associated expenses. Additionally, it will accelerate its drug discovery program by leveraging artificial intelligence.

We will update you on CELZ when more details emerge, subscribe to Microcapdaily to follow along!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Picture by stevepb from Pixabay

 

 

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.